Discontinue use if serious hypersensitivity reaction occurs. Not to be inj in tender, bruised, erythematous, indurated skin or w/ psoriasis. Not to be initiated in patients w/ clinically important active infection. Chronic or history of recurrent infection, or known risk factors for infection. Evaluate for TB prior to initiation; monitor for signs & symptoms of active TB. Not to be given w/ live vaccines during & for at least 21 wk after treatment. Women of childbearing potential should use effective contraception during & for at least 21 wk after treatment. Avoid use during pregnancy. Lactation. Childn & adolescents 5-18 yr; childn <6 yr w/ moderate to severe plaque psoriasis; childn <5 yr w/ psoriatic arthritis.
Sign Out
